Veterinary Medicines

Animeloxan 1.5 mg/ml oral suspension for dogs

Authorised
  • Meloxicam
Download as PDF

Product identification

Medicine name:
Animeloxan 1.5 mg/ml oral suspension for dogs
Animeloxan 1,5 mg/ml suspensie voor oraal gebruik bij honden
Active substance:
  • Meloxicam
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Meloxicam
    1.50
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Oral suspension
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QM01AC06
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Netherlands
Package description:
  • (ID3) 100 millilitre(s): Box (Cardboard) with 1 Bottle (High Density PolyEthylene) with 100 millilitre(s), closed with Lid and Dropper applicator (PolyEthylene, PolyEthylene)
  • (ID1) 10 millilitre(s): Box (Cardboard) with 1 Bottle (High Density PolyEthylene) with 10 millilitre(s), closed with Lid and Dropper applicator (PolyEthylene, PolyEthylene)
  • (ID6) 125 millilitre(s): Box (Cardboard) with 1 Bottle (High Density PolyEthylene) with 125 millilitre(s), closed with Dropper applicator and Lid (PolyEthylene, PolyEthylene)
  • (ID4) 25 millilitre(s): Box (Cardboard) with 1 Bottle (High Density PolyEthylene) with 25 millilitre(s), closed with Dropper applicator and Lid (PolyEthylene, PolyEthylene)
  • (ID5) 50 millilitre(s): Box (Cardboard) with 1 Bottle (High Density PolyEthylene) with 50 millilitre(s), closed with Lid and Dropper applicator (PolyEthylene, PolyEthylene)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • aniMedica GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • aniMedica GmbH
Responsible authority:
  • Medicines Evaluation Board
Authorisation number:
  • REG NL 100187
Date of authorisation status change:
Reference member state:
  • Germany
Procedure number:
  • DE/V/0310/001
Concerned member states:
  • Austria
  • Denmark
  • Hungary
  • Italy
  • Netherlands
  • Poland
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 7/12/2022
Download

Combined File of all Documents

English (PDF)
Published on: 1/09/2023
Updated on: 4/09/2023
Download
Dutch (PDF)
Published on: 30/01/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."